 Patient-reported outcome data from cancer clinical trials does not only have to be statistically analyzed correctly, but has also been reported and presented graphically in a coherent, meaningful and interpretable way. To develop guidance on this is the main focus of Wake Package 4 of the CISACOLA IMI project. Due to preferences and knowledge, the presentation, the reporting and graphical display of patient-reported outcome data might be different between user groups. That's why we included all relevant stakeholders such as patients, physicians, people from the pharmaceutical industry and authorities like the EMA and FDA, HGA specialists and researchers in the development process of the guidelines. Well, in addition to healthcare professionals and other stakeholders like industry representatives, journalists or researchers, Wake Package 4 is very much interested in also gaining the perspective and use of patients and we are succeeding in doing this by conducting interviews also with patients and we managed to get the opinion of 18 patients looking at graphical examples and sharing their views and opinions and also suggestions for improvement. And furthermore, we have a patient expert, which enlarges our Wake Package 4 core team. It's Susanna Leto Dupriolo. She brings not only her knowledge about patient-reported outcome data and clinical trials from her firmer work in industry, but she is also a former patient and so she's able to join our work package with reviewing materials, also critically comment on work processes we are following and thereby advocating for patients in all discussions we have. The main output of Wake Package 4 will be recommendations on how each CISACOL-iMI trial endpoints should be graphically represented. There will be at least one template showing specifically what each recommendation means. In addition, there will be detailed explanation on whether and which special features should be considered for different stakeholders. For example, Kaplan-Meier curves are usually not appropriate to show patients without further explanation, while pie charts contains insufficient information for healthcare providers and other stakeholders. Furthermore, Work Package 4 will also provide guidance on which aspects should be considered for all charts, such as the coloring or clear explanation and structure.